Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 2Gynecologic 1

Conditions

Breast Neoplasms 2551Triple Negative Breast Neoplasms 436Carcinoma, Non-Small-Cell Lung 339Ovarian Neoplasms 315Neoplasms 281Neoplasm Metastasis 253Colorectal Neoplasms 246Stomach Neoplasms 202Pancreatic Neoplasms 196Prostatic Neoplasms 188Lung Neoplasms 180Melanoma 171Squamous Cell Carcinoma of Head and Neck 140Endometrial Neoplasms 140Head and Neck Neoplasms 124Carcinoma, Renal Cell 118Uterine Cervical Neoplasms 104Esophageal Neoplasms 97Urinary Bladder Neoplasms 92Small Cell Lung Carcinoma 87Sarcoma 85Colonic Neoplasms 80Carcinoma, Hepatocellular 62Carcinoma, Transitional Cell 61Kidney Neoplasms 51Advanced Breast Cancer 51Cholangiocarcinoma 50Liver Neoplasms 47Brain Neoplasms 43Mesothelioma 37

Interventions

2,2'-dithiodiethanesulfonic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Paresthesia × Breast × Clear all
NCT00039780 2022-07-13

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
764 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Paresthesia, Neurotoxicity Syndromes

NCT00746694 2015-08-27

A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)

Merck Sharp & Dohme LLC

Completed
154 enrolled 7 charts
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Paresthesia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡